EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment for inflammatory bowel disease with VLA-4 blockers



Treatment for inflammatory bowel disease with VLA-4 blockers



Official Gazette of the United States Patent & Trademark Office Patents 1225(1), Aug 3




(PDF 0-2 workdays service: $29.90)

Accession: 035980216

Download citation: RISBibTeXText



Related references

Recent advances in basic and clinical aspects of inflammatory bowel disease: which steps in the mucosal inflammation should we block for the treatment of inflammatory bowel disease?. World Journal of Gastroenterology 13(15): 2145-2149, 2007

Th17-cytokine blockers as a new approach for treating inflammatory bowel disease. Annals of Medicine 43(3): 172-178, 2011

Open-label, uncontrolled trial of bowel sterilization and repopulation with normal bowel flora for treatment of inflammatory bowel disease. Current Therapeutic Research. 58(12): 1001-1012,., 1997

Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis. Pharmacogenomics 14(14): 1691-1700, 2014

Surgical treatment of inflammatory bowel diseases in northwestern Italy: a multicentric study by the G.S.M.I.I. (Inflammatory Bowel Disease Study Group). Annali Italiani di Chirurgia 74(3): 319-326, 2003

The risk of tuberculosis in Korean patients with inflammatory bowel disease receiving tumor necrosis factor-α blockers. Journal of Korean Medical Science 30(2): 173-179, 2015

Disease outcome in inflammatory bowel disease: Mortality, morbidity and therapeutic management of a 796-person inception cohort in the European collaborative study on inflammatory bowel disease (EC-IBD). Scandinavian Journal of Gastroenterology 35(12): 1272-1277, 2000

Disease outcome in inflammatory bowel disease: mortality, morbidity and therapeutic management of a 796-person inception cohort in the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Scandinavian Journal of Gastroenterology 35(12): 1272-1277, 2001

De novo Crohn's Disease after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis and Inflammatory Bowel Disease Unclassified: Long-Term Follow-Up of a Prospective Inflammatory Bowel Disease Registry. American Surgeon 82(10): 977-981, 2016

Treatment of inflammatory immunologic disease 2. Anti-cytokine therapies in inflammatory bowel disease. Internal Medicine 46(16): 1307-1309, 2007

Childhood onset inflammatory bowel disease: predictors of delayed diagnosis from the CEDATA German-language pediatric inflammatory bowel disease registry. Journal of Pediatrics 158(3): 467-473.E2, 2011

Predictors of temporary and permanent work disability in patients with inflammatory bowel disease: results of the swiss inflammatory bowel disease cohort study. Inflammatory Bowel Diseases 19(4): 847-855, 2013

Advances in detection and management of dysplasia in inflammatory bowel disease: Is endoscopic submucosal dissection ready for prime time in inflammatory bowel disease?. Gastrointestinal Endoscopy 82(4): 739-741, 2016

Rising Educators, Academicians, and Clinicians Helping Inflammatory Bowel Disease (REACH-IBD)-Promoting Improvement of Inflammatory Bowel Disease Education in the United States. Inflammatory Bowel Diseases 22(6): 1531-1532, 2016